+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Islet Amyloid Polypeptide"

Islet Amyloid Polypeptide Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Thumbnail Image

Islet Amyloid Polypeptide Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • August 2024
  • 84 Pages
  • Global
From
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • February 2022
  • 62 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

The Islet Amyloid Polypeptide (IAPP) market is a segment of the Endocrine and Metabolic Disorders Drugs market. IAPP is a hormone produced in the pancreas that is involved in glucose metabolism. It is also known as amylin and is associated with Type 2 diabetes. IAPP is used to treat diabetes by helping to regulate blood sugar levels. It is also used to treat obesity and other metabolic disorders. IAPP is available in both injectable and oral forms. It is typically administered as a once-daily injection or as an oral tablet. The market for IAPP is expected to grow due to the increasing prevalence of diabetes and other metabolic disorders. Some companies in the IAPP market include Novo Nordisk, Eli Lilly, Sanofi, Merck, and AstraZeneca. These companies are involved in the development, manufacture, and marketing of IAPP products. Show Less Read more